Gesynta Pharma is pleased to announce that our application for a clinical phase I study of GS-073 has been approved by the Swedish Medical Products Agency. This significant development represents the commencement of clinical testing for GS-073, aimed at addressing the pressing issue of chronic inflammatory pain. Notably, this approval signifies that two of Gesynta Pharma's drug candidates, both of which are potent and selective mPGES-1 inhibitors, have advanced to the clinical phase.

For further details, please see the press release.